TeleClinic review

What it is

TeleClinic (Teleclinic Holdings LLC) is a cash-pay telehealth platform selling compounded semaglutide and tirzepatide alongside two non-GLP-1 injectables: an NAD⁺ injection and a B12 with MIC lipotropic. Prescriptions are filled by Rush Pharmacy, which TeleClinic describes as a PCAB-accredited 503A compounding pharmacy — a claim we attribute to TeleClinic rather than assert, since our own record of that pharmacy could not independently confirm the accreditation. It operates in 47 states, excluding California, South Carolina and New Jersey, with free shipping and no insurance accepted.

How it works

Asynchronous, cash-pay and unusually well documented for a platform this size. The pharmacy disclosure is quoted verbatim on a dedicated pharmacy-partners page — all prescriptions filled by Rush Pharmacy, a licensed 503A compounding pharmacy authorised under Section 503A — which is a specific, checkable statement rather than a reference to "a US-licensed pharmacy". The state list is explicit and names the exclusions, which is far more useful than a nationwide claim, and the LegitScript seal resolves to a real certificate image rather than a decorative badge. The NAD⁺ product itself is described with a frequency choice — twice weekly to start, three times weekly, or daily — with dosing stated as selected by your provider, though no mg strength is published. Two things to weigh. The PCAB accreditation claim is TeleClinic's, not an independent finding, so treat it as a claim. And its billing structure leans on quarterly commitments across the board: its GLP-1 intro rates are stated as billed quarterly, and its NAD⁺ page offers a three-month option beside a first-month one without ever describing the steady state.

Pricing transparency

Better on its GLP-1 line than on the product this board is about, which is an unusual failure mode. For semaglutide and tirzepatide the site publishes both halves — $139 and $219 a month for the first quarter, billed quarterly, then $199 and $299 ongoing month to month — so a reader can see the real cost of month four. Its NAD⁺ page does not. It reads "1 Month $99 $129" and "3 Months $250 $319", with "$99 billed monthly" beside the frequency selector, and never states what the month-to-month rate becomes once the introductory period ends. A struck-through $129 is a regular-price anchor, not a published ongoing rate, and $250 for three months works out to about $83 a month, which does not reconcile with either figure. Given that the same company publishes its ongoing GLP-1 rates plainly, the silence on NAD⁺ is conspicuous rather than accidental, so we publish no floor. Ask what month four costs before you buy month one. Its B12 with MIC lipotropic is listed at $109 for a first month, with a quarterly rate around $84 a month.

Branded vs compounded

Compounded; not FDA-approved — disclosed by the site itself. Prescription required only if a licensed provider finds it appropriate. Naming the dispensing pharmacy is the single most useful disclosure for an injectable and TeleClinic makes it; compounded sterile products are still not reviewed by the FDA for purity and potency the way approved drugs are, and the PCAB accreditation attached to the pharmacy is TeleClinic's own characterisation rather than something we independently confirmed. On the evidence, the NAD⁺ injection sits at the weak end of the category. There are no controlled human outcome trials for injected NAD⁺ at all; the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears plasma quickly, which tells you about disposal rather than about benefit. The NAD⁺ forms with human trial data are the oral precursors nicotinamide riboside and nicotinamide mononucleotide, and what those trials reliably demonstrate is a raised blood NAD⁺ level — a biomarker, not a demonstrated clinical benefit. The site's frequency ladder, from twice weekly up to daily, is a dosing convention rather than something derived from outcome data, and no mg strength is published for any tier. Individual results vary.

Pros and watch-outs

The evidence behind what TeleClinic prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• NAD injections: how to get them near you or online, and what the evidence really says

  Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

How TeleClinic compares

A few alternatives worth a look, depending on what you’re optimizing for.

• THTablet Health

  People who want NAD⁺ in either injection or nasal-spray form from a platform that names its pharmacies

  See Tablet Health →
• SHStealth Health

  People who want to compare injectable NAD⁺ against oral nicotinamide riboside on one menu

  See Stealth Health →
• RHRylo Health

  NAD⁺ buyers who want a named pharmacy and the month-to-month rate stated up front

  See Rylo Health →